ClinicalTrials.gg
CompletedNCT01941095Updated Nov 13, 2018Results posted

A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis

A Phase 3 interventional study of Azathioprine and Chloroquine in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 10 sites in Greece. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-13.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
67th of 113
100 · median 130
Started
2013
with 4 others
Phase 3
47 of 113
1 open now
Registered
75th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 67th largest by enrollment, is one of 5 that started in 2013, is one of 47 in phase 3, and was the 75th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This Phase IIIb, multicenter, open label, single arm study will evaluate the safety and efficacy of subcutaneous (SC) tocilizumab as monotherapy or in combination with methotrexate or other non-biologic DMARDs in participants with active rheumatoid arthritis who are either naïve to or have an inadequate response to prior non-biologic or/and biologic DMARDs. The anticipated time on study treatment is 52 weeks. Those participants who will complete the 60-week study period and have achieved Disease Activity Score 28 (DAS28) remission or a good European League Against Rheumatism (EULAR) response at 52 weeks will be eligible to enter the extension phase until tocilizumab is commercially available and reimbursed in Greece.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of active rheumatoid arthritis according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria
  • Oral (less than or equal to [\</=] 10 milligrams per day [mg/day] prednisolone or equivalent) and non-steroidal anti-inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for greater than or equal to [>/=] 4 weeks prior to baseline
  • Permitted non biologic DMARDs are allowed if a stable dose for at least 4 weeks prior to baseline
  • Receiving treatment on an outpatient basis, not including tocilizumab
  • Females of and males with female partners of childbearing potential must agree to use a reliable means of during the study; females of childbearing potential must use a reliable means of contraception for at least 3 month following the last dose of tocilizumab

Exclusion criteria

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following baseline
  • Rheumatic disease other than rheumatoid arthritis; secondary Sjögren's syndrome with rheumatoid arthritis is permitted
  • Functional Class 4 as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis
  • Diagnosis of juvenile idiopathic arthritis or juvenile rheumatoid arthritis and/or rheumatoid arthritis before the age of 16
  • Prior history of or current inflammatory joint disease other than rheumatoid arthritis
  • Participants with lack of peripheral venous access
  • Exposure to tocilizumab (either intravenous [IV] or SC) at any time prior to baseline
  • Treatment with any agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of screening
  • Previous treatment with any cell-depending therapies
  • Treatment with IV gamma globulin, plasmapheresis within 6 months of baseline
  • Intra-articular or parenteral within 4 weeks prior to baseline
  • Immunization with a live/attenuated vaccine within 4 weeks prior to baseline
  • Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation
  • History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies
  • Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal disease
  • Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections
  • Any major episode of infection requiring hospitalization of treatment with IV antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks of screening
  • Active tuberculosis (TB) requiring treatment within the previous 3 years
  • Positive for surface antigen or antibody
  • Primary or secondary immunodeficiency (history of or currently active)
  • Evidence of active malignant disease, diagnosed within the previous 10 years (except for basal and squamous cell carcinoma of the skin or carcinoma in situ of the cervix uteri that has been excised and cured), or breast cancer diagnosed within the previous 20 years
  • Pregnant or breast feeding women
  • History of alcohol, drug or chemical abuse within 1 year prior to screening
  • Neuropathies or other conditions that interfere with pain evaluation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Tocilizumab

    Participants will receive tocilizumab 162 milligrams (mg) SC injection once a week (QW) either as monotherapy or in combination with methotrexate or other non-biologic DMARDs during the treatment period of 52 weeks. The choice of monotherapy or combination treatment is according to the physician's judgment up to Week 24. Depending upon the participant's response to study regimen at Week 24, participant may either continue/discontinue/switch to tocilizumab monotherapy or may lead to intensification of methotrexate/non-biologic DMARDs with tocilizumab at a fixed dose of 162 mg SC QW till Week 52. After Week 52, participants who remain in study will enter a 8 week wash-out period and then (from Week 60) will proceed to the extension phase until tocilizumab is commercially available in Greece. Permitted DMARDs include methotrexate, azathioprine, chloroquine, hydroxychloroquine, leflunomide, and sulfasalazine.

    Drug: Azathioprine · Drug: Chloroquine · Drug: Hydroxychloroquine · Drug: Leflunomide · Drug: Methotrexate · Drug: Sulfasalazine · Drug: Tocilizumab

Interventions

  • Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to baseline.

  • Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.

    Also known as: RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24

    DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health \[GH\]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour \[mm/hr\]). The score is calculated using the following formula: DAS28-ESR = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (\<) 2.6 represents DAS28-ESR remission.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24

    DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy.

    Time frame: Weeks 24, 28, 32, 36, 40, 44, 48, 52

  2. Percentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24

    DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (\>/=) 2.6 and \<3.2 represents LDA.

    Time frame: Weeks 28, 32, 36, 40, 44, 48, 52

  3. Change From Baseline in DAS28-ESR up to Week 52

    DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement.

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  4. Number of Participants With American College of Rheumatology 20 (ACR20) Response

    ACR20 response was defined as \>/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10).

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  5. Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria

    Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \</=5.1 with reduction of \>0.6 to \</=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \</=1.2 points, or any score with reduction \</=0.6 points, were assessed as having 'no response'.

    Time frame: Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  6. Change From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52

    SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter \[cm\]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter \[mg/dL\]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score \</=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  7. Change From Baseline in TJC28 up to Week 52

    28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement.

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  8. Change From Baseline in SJC28 up to Week 52

    28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement.

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  9. Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation

    Time frame: From Baseline up to Week 52

  10. Number of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation

    Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported.

    Time frame: From Baseline up to Week 52

  11. Number of Participants With Anti-Tocilizumab Antibodies (ATA)

    All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately.

    Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

  12. Soluble Interleukin-6 Receptor (sIL-6R) Levels

    Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

  13. Tocilizumab Serum Levels

    Time frame: Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)

  14. PGA, Using VAS Score

    PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  15. Patient Assessment of Pain, Using VAS Score

    The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no pain" and the extreme right end = 100 mm, and was described as "unbearable pain". Higher values correspond to worst state of participant (higher level of pain).

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  16. HAQ-DI Score

    The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  17. Percentage of Participants Who Received All Planned Study Medication (Compliance)

    Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records.

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

  18. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score

    FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score).

    Time frame: Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52

07

Results

Posted Nov 13, 2018

Participant flow

Participants were enrolled in 9 locations in Greece

Participant flow — Overall Study
MilestoneTocilizumab
Started97
Completed41
Not completed56
Withdrew: Insufficient therapeutic response13
Withdrew: Anaphylaxis or serious hypersensitivity2
Withdrew: Adverse event11
Withdrew: Physician decision3
Withdrew: Withdrawal by subject17
Withdrew: Lost to follow-up10

Outcome measures

PrimaryPercentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using tender joint count in 28 joints (TJC28), swollen joint count in 28 joints (SJC28), patient global assessment of disease activity (PGA) (general health \[GH\]) using visual analog scale (VAS): 0 millimeter (mm)=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in millimeters per hour \[mm/hr\]). The score is calculated using the following formula: DAS28-ESR = \[0.56 multiplied by (\*) square root (√) of TJC28\] plus (+) \[0.28\*√SJC28\]+\[0.70\*the natural logarithm (ln) ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score of less than (\<) 2.6 represents DAS28-ESR remission.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 24
percentage of participantsTocilizumab
Percentage of Participants Who Achieved Disease Activity Score Based on 28 Joint Count and Erythrocyte Sedimentation Rate (DAS28-ESR) Remission at Week 2440
SecondaryPercentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. The percentage reported for Week 24 is based on confirmation on switching to SC tocilizumab monotherapy.

Time frame:
Weeks 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Maintained DAS28-ESR Remission From Week 24 up to Week 52 Among Participants on Tocilizumab Monotherapy Since Week 24
percentage of participantsTocilizumab
Week 2438.7
Week 2834.2
Week 3236.5
Week 3636.5
Week 4036.5
Week 4435.2
Week 4835.7
Week 5238.8
SecondaryPercentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. DAS28-ESR score \<2.6 represents DAS28-ESR remission. DAS28-ESR score greater than or equal to (\>/=) 2.6 and \<3.2 represents LDA.

Time frame:
Weeks 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28-ESR Remission/Low Disease Activity (LDA) From Week 28 up to Week 52 Among Participants With Intensification of Methotrexate/Other Non-Biologic DMARDs in Combination With Tocilizumab Since Week 24
percentage of participantsTocilizumab
Week 28: Remission5.1
Week 32: Remission8.1
Week 36: Remission4.1
Week 40: Remission9.5
Week 44: Remission6.9
Week 48: Remission8.5
Week 52: Remission6
Week 28: LDA7.6
Week 32: LDA1.4
Week 36: LDA6.8
Week 40: LDA6.8
Week 44: LDA6.9
Week 48: LDA4.2
Week 52: LDA9
SecondaryChange From Baseline in DAS28-ESR up to Week 52

DAS28-ESR score is a measure of participant's disease activity calculated using TJC28, SJC28, PGA using VAS 0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS, and acute phase response (ESR in mm/hr) for a total possible score of 0 to 10. The score is calculated using the following formula: DAS28-ESR = \[0.56 \* √TJC28 + \[0.28\*√SJC28\]+\[0.70\*ln ESR\]+\[0.014\*GH\]. DAS28-ESR score varies from 0 to 10, where higher scores represent greater disease activity. A negative change from baseline indicates an improvement.

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · units on a scale
Change From Baseline in DAS28-ESR up to Week 52
units on a scaleTocilizumab
Change at Week 2-0.99 (-1.33 to -0.64)
Change at Week 4-1.70 (-2.06 to -1.36)
Change at Week 8-2.20 (-2.54 to -1.84)
Change at Week 12-2.56 (-2.91 to -2.20)
Change at Week 16-2.59 (-2.91 to -2.27)
Change at Week 20-2.93 (-3.24 to -2.62)
Change at Week 24-3.14 (-3.45 to -2.83)
Change at Week 28-3.22 (-3.53 to -2.90)
Change at Week 32-3.34 (-3.66 to -3.01)
Change at Week 36-3.32 (-3.64 to -3.00)
Change at Week 40-3.40 (-3.73 to -3.07)
Change at Week 44-3.45 (-3.78 to -3.11)
Change at Week 48-3.42 (-3.76 to -3.08)
Change at Week 52-3.40 (-3.73 to -3.07)
SecondaryNumber of Participants With American College of Rheumatology 20 (ACR20) Response

ACR20 response was defined as \>/=20% improvement from baseline in both TJC28 and SJC28 as well as in 3 out of 5 additional parameters: Separate patient and physician's global assessment of disease activity on VAS (0 mm=no disease activity to 100 mm=maximum disease activity, displayed on the 100 mm horizontal VAS), patient's assessment of pain on VAS (0 mm=no pain to 100 mm=unbearable pain, displayed on the 100 mm horizontal VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without any difficulty to 3=unable to do), and acute phase response (ESR in mm/hr, for a total possible score of 0 to 10).

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · participants
Number of Participants With American College of Rheumatology 20 (ACR20) Response
participantsTocilizumab
Week 219
Week 419
Week 823
Week 129
Week 1613
Week 2016
Week 249
Week 2813
Week 3210
Week 3611
Week 4010
Week 4412
Week 4813
Week 5215
SecondaryPercentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria

Response to treatment was determined using EULAR criteria based upon DAS28 absolute scores at the assessment visit and the DAS28 reduction from the baseline visit. Participants with a score lesser than or equal to (\</=) 3.2 and reduction of greater than (\>) 1.2 points were assessed as having a 'good' response. Participants with a score \>3.2 with reduction of \>1.2 points, or a score \</=5.1 with reduction of \>0.6 to \</=1.2 points, were assessed as having a 'moderate' response. Participants with a score \>5.1 with reduction of \>0.6 to \</=1.2 points, or any score with reduction \</=0.6 points, were assessed as having 'no response'.

Time frame:
Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · percentage of participants
Percentage of Participants With Good, Moderate, or No Response According to European League Against Rheumatism (EULAR) Response Criteria
percentage of participantsTocilizumab
Week 2: Good response9.4
Week 2: Moderate response44.8
Week 2: No response45.8
Week 4: Good response9.5
Week 4: Moderate response38.9
Week 4: No response51.6
Week 8: Good response10.8
Week 8: Moderate response23.6
Week 8: No response65.6
Week 12: Good response9.2
Week 12: Moderate response20.7
Week 12: No response70.1
Week 16: Good response5.9
Week 16: Moderate response15.3
Week 16: No response78.8
Week 20: Good response6.1
Week 20: Moderate response26.8
Week 20: No response67.1
Week 24: Good response6.2
Week 24: Moderate response21.2
Week 24: No response72.6
Week 28: Good response6.3
Week 28: Moderate response11.4
Week 28: No response82.3
Week 32: Good response0
Week 32: Moderate response18.9
Week 32: No response81.1
Week 36: Good response1.3
Week 36: Moderate response14.9
Week 36: No response83.8
Week 40: Good response5.4
Week 40: Moderate response17.6
Week 40: No response77
Week 44: Good response2.8
Week 44: Moderate response13.9
Week 44: No response83.3
Week 48: Good response5.7
Week 48: Moderate response11.4
Week 48: No response82.9
Week 52: Good response94
Week 52: Moderate response6
Week 52: No response0
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52

SDAI is an index for measuring disease activity. SDAI is the numerical sum of five outcome parameters: TJC28 and SJC28, PGA and physician global assessment of disease activity assessed on VAS (0 centimeter \[cm\]-10 cm); 0 cm= no disease activity and 10 cm= worst disease activity, and CRP (in milligrams per deciliter \[mg/dL\]). SDAI total score ranges from 0 to 86, with higher scores indicating increased (or severe) disease activity. SDAI score \</=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) Score up to Week 52
units on a scaleTocilizumab
Change at Week 2-3.41 (-7.17 to 0.12)
Change at Week 4-6.54 (-10.26 to -2.97)
Change at Week 8-8.72 (-12.89 to -5.18)
Change at Week 12-11.07 (-14.74 to -8.04)
Change at Week 16-13.47 (-17.00 to -10.60)
Change at Week 20-13.88 (-17.42 to -10.94)
Change at Week 24-14.08 (-17.72 to -11.25)
Change at Week 28-15.37 (-18.87 to -12.41)
Change at Week 32-16.09 (-19.63 to -13.07)
Change at Week 36-15.61 (-19.14 to -12.58)
Change at Week 40-14.86 (-18.66 to -11.84)
Change at Week 44-16.31 (-20.06 to -13.24)
Change at Week 48-16.47 (-20.13 to -13.45)
Change at Week 52-17.35 (-21.01 to -14.16)
SecondaryChange From Baseline in TJC28 up to Week 52

28 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 28. A negative change from baseline indicated improvement.

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · tender joints
Change From Baseline in TJC28 up to Week 52
tender jointsTocilizumab
Change at Week 2-1.30 (-3.18 to 0.56)
Change at Week 4-3.26 (-5.09 to -1.42)
Change at Week 8-4.97 (-6.69 to -3.25)
Change at Week 12-5.82 (-7.55 to -4.09)
Change at Week 16-6.39 (-8.08 to -4.70)
Change at Week 20-7.03 (-8.67 to -5.38)
Change at Week 24-7.72 (-9.34 to -6.09)
Change at Week 28-7.91 (-9.51 to -6.31)
Change at Week 32-8.38 (-10.00 to -6.77)
Change at Week 36-8.28 (-9.86 to -6.66)
Change at Week 40-8.22 (-9.84 to -6.59)
Change at Week 44-8.63 (-10.25 to -7.01)
Change at Week 48-8.26 (-9.97 to -6.54)
Change at Week 52-8.75 (-10.41 to -7.09)
SecondaryChange From Baseline in SJC28 up to Week 52

28 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 28. A negative change from baseline indicated improvement.

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · swollen joints
Change From Baseline in SJC28 up to Week 52
swollen jointsTocilizumab
Change at Week 2-1.82 (-3.51 to -0.13)
Change at Week 4-3.08 (-4.70 to -1.46)
Change at Week 8-4.71 (-6.20 to -3.21)
Change at Week 12-5.24 (-6.68 to -3.79)
Change at Week 16-5.79 (-7.27 to -4.31)
Change at Week 20-6.06 (-7.55 to -4.57)
Change at Week 24-6.60 (-8.03 to -5.18)
Change at Week 28-6.65 (-8.09 to -5.21)
Change at Week 32-6.73 (-8.19 to -5.27)
Change at Week 36-6.76 (-8.22 to -5.28)
Change at Week 40-6.91 (-8.37 to -5.44)
Change at Week 44-6.82 (-8.31 to -5.33)
Change at Week 48-6.63 (-8.15 to -5.10)
Change at Week 52-6.98 (-8.52 to -5.44)
SecondaryPercentage of Participants With Corticosteroid Dose Reduction or Discontinuation
Time frame:
From Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation
percentage of participantsTocilizumab
Percentage of Participants With Corticosteroid Dose Reduction or Discontinuation48.6
SecondaryNumber of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation

Reasons for corticosteroid dose reduction included: Safety Reasons (including elevated liver function test results, respiratory infections, infections and infestations, gastrointestinal disorders etc.); Other Reasons (disease remission, improvement etc.); and Unknown Reasons (including no reason). Number of participants by reasons (Safety, Other, Unknown) for corticosteroid dose reduction or discontinuation were reported.

Time frame:
From Baseline up to Week 52
Reported as:
Number · participants
Number of Participants by Reasons (Categories) for Corticosteroid Dose Reduction or Discontinuation
participantsTocilizumab
Safety6
Other10
Unknown2
SecondaryNumber of Participants With Anti-Tocilizumab Antibodies (ATA)

All samples were tested using a screening assay and, if positive, by a confirmation assay to determine specificity and a neutralizing assay to test for the ability to inhibit the activity of tocilizumab. Number of participants with a positive assay result for screening assay (ATA - Screen), confirmatory assay (ATA - Confirmatory), and neutralizing assay (ATA - Neutralizing) was reported separately.

Time frame:
Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
Reported as:
Number · participants
Number of Participants With Anti-Tocilizumab Antibodies (ATA)
participantsTocilizumab
Week 1: ATA - Screen7
Week 1: ATA - Confirmatory4
Week 1: ATA - Neutralizing0
Week 12: ATA - Screen3
Week 12: ATA - Confirmatory0
Week 12: ATA - Neutralizing0
Week 24: ATA - Screen3
Week 24: ATA - Confirmatory1
Week 24: ATA - Neutralizing1
Week 36: ATA - Screen2
Week 36: ATA - Confirmatory0
Week 36: ATA - Neutralizing0
Week 52: ATA - Screen2
Week 52: ATA - Confirmatory0
Week 52: ATA - Neutralizing0
Week 60: ATA - Screen1
Week 60: ATA - Confirmatory1
Week 60: ATA - Neutralizing0
SecondarySoluble Interleukin-6 Receptor (sIL-6R) Levels
Time frame:
Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
Reported as:
Mean · nanograms per milliliter (ng/mL)
Soluble Interleukin-6 Receptor (sIL-6R) Levels
nanograms per milliliter (ng/mL)Tocilizumab
Week 139450 ± 10740
Week 12553.43 ± 120.36
Week 24572.03 ± 136.68
Week 36570.78 ± 139.16
Week 52537.73 ± 152.55
Week 6042850 ± 13800
SecondaryTocilizumab Serum Levels
Time frame:
Baseline (Week 1), Weeks 12, 24, 36, 52, and 8 weeks after Week 52 dose (Week 60)
Reported as:
Mean · microgrms per milliliter (mcg/mL)
Tocilizumab Serum Levels
microgrms per milliliter (mcg/mL)Tocilizumab
Week 10.38 ± 0.17
Week 1241.98 ± 25.04
Week 2444.67 ± 28.83
Week 3647.90 ± 28.29
Week 5245.37 ± 28.13
Week 606.46 ± 4.28
SecondaryPGA, Using VAS Score

PGA was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the extreme right end = 100 mm, and was described as "maximum disease activity" (maximum arthritis disease activity). Higher values correspond to worst state of participant (high disease activity).

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · mm
PGA, Using VAS Score
mmTocilizumab
Week 128.26 ± 20.25
Week 227.57 ± 20.08
Week 428.36 ± 19.37
Week 832.28 ± 22.09
Week 1228.73 ± 23.01
Week 1624.40 ± 19.02
Week 2028.15 ± 20.22
Week 2432.63 ± 23.44
Week 2826.02 ± 18.79
Week 3227.08 ± 20.98
Week 3630.79 ± 22.37
Week 4030.50 ± 21.93
Week 4425.79 ± 16.33
Week 4823.86 ± 19.11
Week 5223.08 ± 17.08
SecondaryPatient Assessment of Pain, Using VAS Score

The participant's level of pain was assessed on a 0 to 100 mm horizontal VAS. The extreme left end of the line = 0 mm, and was described as "no pain" and the extreme right end = 100 mm, and was described as "unbearable pain". Higher values correspond to worst state of participant (higher level of pain).

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · mm
Patient Assessment of Pain, Using VAS Score
mmTocilizumab
Week 146.40 ± 27.43
Week 252.04 ± 24.46
Week 449.87 ± 23.35
Week 842.72 ± 23.20
Week 1237.21 ± 21.29
Week 1634.24 ± 22.49
Week 2031.00 ± 19.42
Week 2429.57 ± 19.66
Week 2829.63 ± 19.07
Week 3225.50 ± 17.95
Week 3626.78 ± 22.13
Week 4027.50 ± 21.93
Week 4426.88 ± 19.96
Week 4823.61 ± 18.63
Week 5223.98 ± 20.19
SecondaryHAQ-DI Score

The Stanford HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Responses in each component set were scored from 0 (without any difficulty) to 3 (unable to do). The highest score recorded for any question in a category determines the score for the category, unless aids, devices, or help from another person was required. The HAQ-DI score was calculated as the sum of the category scores divided by the number of categories scored, giving a possible range of scores from 0 to 3. Scores of 0 to 1 are generally considered to represent "mild to moderate difficulty", 1 to 2 as "moderate to severe disability", and 2 to 3 as "severe to very severe disability".

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · units on a scale
HAQ-DI Score
units on a scaleTocilizumab
Week 11.31 ± 0.66
Week 21.22 ± 0.64
Week 41.09 ± 0.66
Week 80.91 ± 0.66
Week 120.82 ± 0.58
Week 160.72 ± 0.59
Week 200.68 ± 0.56
Week 240.66 ± 0.55
Week 280.66 ± 0.57
Week 320.59 ± 0.58
Week 360.63 ± 0.58
Week 400.60 ± 0.59
Week 440.59 ± 0.61
Week 480.56 ± 0.59
Week 520.54 ± 0.60
SecondaryPercentage of Participants Who Received All Planned Study Medication (Compliance)

Compliance (in terms of percentage of participants who received all planned study medication) was assessed on the basis of participant diary cards and return records.

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Received All Planned Study Medication (Compliance)
percentage of participantsTocilizumab
Week 166
Week 297.9
Week 4100
Week 8100
Week 1298.9
Week 1697.6
Week 2098.8
Week 24100
Week 28100
Week 32100
Week 36100
Week 40100
Week 44100
Week 48100
Week 52100
SecondaryFunctional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score

FACIT-Fatigue total score is sum of FACIT-General subscale score and FACIT-Fatigue (additional concerns) subscale score. FACT-General consists of 27 questions grouped in 4 domains of general health-related quality of life: physical well-being, social/family well-being, emotional well-being, and functional well-being; each item ranges from 0 (not at all) to 4 (very much). FACT-General score ranges between 0-108. FACIT-Fatigue subscale is a 13-item questionnaire that evaluates self-reported fatigue and its impact upon daily activities. Each item ranges from 0 (Not at all) to 4 (Very much). For all items, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-Fatigue subscale score for a total possible score of 0 (worse score) to 52 (better score). FACIT-Fatigue total score (FACT-G plus FACT-F subscale scores) ranges from 0 (better score) to 160 (worse score).

Time frame:
Baseline (Week 1), Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52
Reported as:
Mean · units on a scale
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Total Score
units on a scaleTocilizumab
Week 189.68 ± 24.32
Week 291.83 ± 22.91
Week 4100.38 ± 24.36
Week 8103.16 ± 26.28
Week 12106.39 ± 24.74
Week 16110.17 ± 24.96
Week 20112.60 ± 25.50
Week 24114.21 ± 25.23
Week 28114.85 ± 26.95
Week 32117.01 ± 26.00
Week 36116.50 ± 26.17
Week 40116.59 ± 26.20
Week 44119.67 ± 26.64
Week 48119.83 ± 26.51
Week 52121.82 ± 25.34

Adverse events

Collected over From Baseline up to end of study (Week 60). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab Monotherapy—2/31 (6.5%)19/31 (61.3%)
Tocilizumab + Methotrexate or Other Non-Biologic DMARDs—5/66 (7.6%)38/66 (57.6%)
Most frequent serious events
Most frequent serious events
EventTocilizumab MonotherapyTocilizumab + Methotrexate or Other Non-Biologic DMARDs
DiarrhoeaGastrointestinal disorders1/311/66
Respiratory tract infectionInfections and infestations1/310/66
DehydrationMetabolism and nutrition disorders1/310/66
DyspnoeaRespiratory, thoracic and mediastinal disorders0/312/66
Acute coronary syndromeCardiac disorders0/311/66
Pancreatitis acuteGastrointestinal disorders0/311/66
BronchitisInfections and infestations0/311/66
Most frequent other events
Showing 10 of 33
Most frequent other events
EventTocilizumab MonotherapyTocilizumab + Methotrexate or Other Non-Biologic DMARDs
Alanine aminotransferase increasedInvestigations9/3113/66
Aspartate aminotransferase increasedInvestigations8/319/66
NeutropeniaBlood and lymphatic system disorders6/315/66
PruritusSkin and subcutaneous tissue disorders5/314/66
LeukopeniaBlood and lymphatic system disorders4/318/66
NauseaGastrointestinal disorders4/310/66
NasopharyngitisInfections and infestations4/318/66
BronchitisInfections and infestations3/315/66
ContusionInjury, poisoning and procedural complications3/312/66
Blood triglycerides increasedInvestigations3/313/66

Baseline characteristics

Full analysis set included all recruited participants who received at least one dose of SC tocilizumab.

Age, Continuous
Age, Continuous(years)Tocilizumab
Mean56.27 ± 12.77
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab
Female86
Male11
08

Study locations

10 sites
  • District Gen. Hosp. of Athens Laiko; A Propedeutic Internal Medicine Clinic & Research Center
    Athens, 115 27, Greece
  • Laiko General Hospital; Dept. of Pathophysiology-Uni of Athens
    Athens, 115 27, Greece
  • Hippokratio Hospital; 2Nd Internal Medicine
    Athens, 11527, Greece
  • ATTIKO Hospital_4th University Internal Medicine Clinic
    Haidari, 124 62, Greece
  • Uni General Hospital of Heraklion; Medicine and Rheumatology Clinical Immunology and Allergy Dept
    Heraklion, 711 10, Greece
  • Uni Hospital of Ioannina; Rheumatology
    Ioannina, 455 00, Greece
  • University General Hospital of Larissa; Rheumatology Unit
    Larissa, 411 10, Greece
  • University Hospital of Patras; Rheumatology
    Patras, 265 04, Greece
  • EUROMEDICA Geniki Kliniki Thessalonikis; Rheumatology Department
    Thessaloniki, 544 65, Greece
  • General Hospital of Thessaloniki HIPPOKRATIO; Clinical Immunology Unit,2nd Dept of Internal Medicine
    Thessaloniki, 546 42, Greece
09

References and documents

Publications

  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Petho-Schramm A. Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis. Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393. PubMed 30649524 ↗
  • Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Petho-Schramm A. Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum In: Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. PubMed 29244149 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Jul 2016, 31 months.

Results were first posted in Nov 2018, 2 years 4 months after primary completion.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 31 months is above that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2013
First posted
Sep 13, 2013
StartActual
Nov 20, 2013
Primary completionActual
Jul 10, 2016
CompletionActual
Jul 10, 2016
Results first posted
Nov 13, 2018
Last update
Nov 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01941095
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 13, 2013
Start date
Nov 20, 2013
Primary completion
Jul 10, 2016
Completion
Jul 10, 2016
Results posted
Nov 13, 2018
Last update
Nov 13, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Methotrexate · Tocilizumab

Start the discussion